Akebia Therapeutics shareholders reject proposal to increase share reserve by 9.8M shares

Akebia Therapeutics, Inc.

Three Class I directors elected: Ronald E. Frieson, Steven C. Gilman, Ph.D., Cynthia Smith.
Proposal to increase 2023 Stock Incentive Plan by 9.8M shares failed (52.8M against vs 45.2M for).
Advisory say-on-pay compensation approved narrowly (48.9M for, 47.4M against).
Ratification of Ernst & Young as independent auditor for FY 2024 approved (120.2M for).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.